ArticleNature genetics2017
Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.
Abstract read
In one paragraph
Article in Nature genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 132 citations in OpenAlex.
- Trial
- The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.Neoplasia (New York, N.Y.) · 2026Article
- Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.Leukemia · 2026Article
- Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC.Communications biology · 2025Article
- A non-canonical lymphoblast in refractory childhood T-cell leukaemia.Nature communications · 2025Article
- Association ofCurrent issues in molecular biology · 2025Article
- T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.Leukemia · 2025Review
- FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia.Science advances · 2025Article
- Article
- Oncogenomic profiling in infant-toddler T-ALL identifies NKX2 family genes as drivers linked to favorable outcomes.HemaSphere · 2025Article
- Review
- HLA-vaccine transplantations for refractory leukemia: beyond double-unit cord blood.Frontiers in immunology · 2025Article
- Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.Leukemia · 2024Article
- Decreased PU.1 expression in mature B cells induces lymphomagenesis.Cancer science · 2024Article
- Targeted RNA Sequencing of Head and Neck Adenoid Cystic Carcinoma Reveals SEC16A::NOTCH1 Fusion and MET Exon 14 Skipping as Potentially Actionable Alterations.Head and neck pathology · 2024Article
- SPI1Journal for immunotherapy of cancer · 2024Article
- Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk.Cancer discovery · 2024Article
- Article
- Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024Review
- Pivotal role of BCL11B in the immune, hematopoietic and nervous systems: a review of the BCL11B-associated phenotypes from the genetic perspective.Genes and immunity · 2024Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 19 institutions in 1 country.
Masafumi SekiDepartment of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Shunsuke KimuraDepartment of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Tomoya IsobeDepartment of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3487-3307
Kenichi YoshidaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroo UenoDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yaeko Nakajima-TakagiDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Changshan WangDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Lin LinDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
Ayana KonDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiromichi SuzukiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yusuke ShiozawaDepartment of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Keisuke KataokaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-8263-9902
Yoichi FujiiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuichi ShiraishiLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Kenichi ChibaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Hiroko TanakaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Teppei ShimamuraDivision of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kyoko MasudaLaboratory of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Hiroshi KawamotoLaboratory of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Kentaro OhkiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Motohiro KatoDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Yuki ArakawaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Ryoji HanadaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Hiroshi MoritakeDivision of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Masaharu AkiyamaDepartment of Pediatrics, Jikei University School of Medicine, Tokyo, Japan.
Ryoji KobayashiDepartment of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.
Takao DeguchiDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Yoshiko HashiiDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Atsushi SatoDepartment of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Akira OkaDepartment of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Yasuhide HayashiGunma Children's Medical Center, Shibukawa, Japan.
Masatoshi TakagiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7580-9184
Atsushi ManabeDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Akira OharaDepartment of Pediatrics, Toho University, Tokyo, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Masashi SanadaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Atsushi IwamaDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroyuki ManoDepartment of Cellular Signaling, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2452-6520
Kyoto University · JPThe University of Tokyo · JPChiba University · JPNational Center For Child Health and Development · JPSaitama Children's Medical Center · JPNational Hospital Organization · JPTokyo Medical and Dental University · JPGunma Children's Medical Center · JPHiroshima University · JPJikei University School of Medicine · JPKyoto Prefectural University of Medicine · JPMie University · JPMiyagi Children's Hospital · JPNagoya University · JPSapporo Hokuyu Hospital · JPSt. Luke's International Hospital · JPThe University of Osaka · JPToho University · JPUniversity of Miyazaki · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outcome of treatment-refractory and/or relapsed pediatric T cell acute lymphoblastic leukemia (T-ALL) is extremely poor, and the genetic basis for this is not well understood. Here we report comprehensive profiling of 121 cases of pediatric T-ALL using transcriptome and/or targeted capture sequencing, through which we identified new recurrent gene fusions involving SPI1 (STMN1-SPI1 and TCF7-SPI1). Cases positive for fusions involving SPI1 (encoding PU.1), accounting for 3.9% (7/181) of the examined pediatric T-ALL cases, showed a double-negative (DN; CD4
Indexed as
Gene FusionAdolescentChildChild, PreschoolFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansInfantMalePrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Survival AnalysisT-Lymphocyte SubsetsTrans-ActivatorsProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-Activators
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.